Imaging-based Phenotypic Screening is a extremely powerful and flexible approach to drug discovery and pre-clinical research.
Learn how imaging-based phenotypic assays work and what kind of information you can expect from working with us.
WHAT ARE SOME OF THE CHALLENGES ASSOCIATED WITH PHENOTYPIC ASSAYS?
Target Identification One major criticism of phenotypic approaches is that since target information is not known a priori, eventually there will need to be some effort directed towards target identification or deconvolution. This is a fair criticism but should be weighed against the potential of finding new targets from phenotypic studies rather than pursuing a relatively small number of druggable targets in an increasingly competitive market.
In recent years, there have been significant advances in both siRNA and CRISPR approaches that enable scientists to identify genes and pathways involved in an observed phenotype. Phenovista partners with leading reagent providers to generate custom library screens that fit the scope of your research.
It is also worth noting that hybrid assays that combine phenotypic and target-centric readouts are commonly developed to address this concern. Learn more about this hybrid approach here >>>
Phenotypic assays that use imaging, specifically automated quantitative fluorescence microscopy or high content screening (HCS), bring their own set of challenges. We’ve tried to address how we tackle these challenges but if you have other concerns please contact us.